Disease · MONDO_0020547
Comparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 26
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ibrutinib vs Placebo: deaths from any cause | 23 of 94 | 22 of 96 | 190 | NCT02959944 | Trial comparisons |
| Ibrutinib vs Placebo: serious adverse events | 51 of 94 | 49 of 96 | 190 | NCT02959944 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Open Label Systemic Treatment Because of Inadequate Response to Primary Therapy | 24 of 74 | 25 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: End of Systemic Treatment | 15 of 74 | 15 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Death or Recurrent Malignancy | 25 of 74 | 15 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Definitive Absence of Efficacy Success | 45 of 74 | 40 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Cure of Chronic GVHD Without Resorting to Secondary Systemic Therapy | 11 of 74 | 10 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Withdrawal of Prednisone | 30 of 74 | 33 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Bronchiolitis Obliterans | 5 of 74 | 4 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Recurrent Malignancy | 17 of 74 | 10 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Death | 19 of 74 | 10 of 77 | 151 | NCT00089141 | Trial comparisons |
| Mycophenolate Mofetil vs Placebo: Non-relapse Mortality | 8 of 74 | 5 of 77 | 151 | NCT00089141 | Trial comparisons |
| ENTO vs Placebo: deaths from any cause | 1 of 32 | 0 of 33 | 65 | NCT02701634 | Trial comparisons |
| ENTO vs Placebo: serious adverse events | 15 of 32 | 11 of 33 | 65 | NCT02701634 | Trial comparisons |
| Arm I (Enzyme Inhibitor) vs Arm II (Monoclonal Antibody): Significant Clinical Response | 9 of 30 | 10 of 31 | 61 | NCT01309997 | Trial comparisons |
| Arm 1 (Enzyme Inhibitor) vs Arm II (Monocolonal Antibody): Number of Patients Achieving Improvement in Cutaneous Sclerosis | 2 of 30 | 9 of 31 | 61 | NCT01309997 | Trial comparisons |
Arm I (Enzyme Inhibitor) vs Arm II (Monoclonal Antibody): Patients With Any Percentage Decline in Any Grade of Sclerosis Without Increase in Percentage of Higher Grades of Sclerosis in Other Areas on the Vienna Skin Scale | 14 of 30 | 9 of 31 | 61 | NCT01309997 | Trial comparisons |
| Arm I (Enzyme Inhibitor) vs Arm II (Monoclonal Antibody): Cumulative Incidence of Treatment Failure | 24 of 30 | 26 of 31 | 61 | NCT01309997 | Trial comparisons |
| ECP Methoxsalen + SoC vs Standard of Care (SoC): deaths from any cause | 4 of 29 | 0 of 31 | 60 | NCT01380535 | Trial comparisons |
| Arm I (Enzyme Inhibitor) vs Arm II (Monoclonal Antibody): Patients Who Were Able to Taper Corticosteroids | 7 of 27 | 9 of 32 | 59 | NCT01309997 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020547/comparisons